Inteum Company
Links
Visible Legacy
RSS
News & Resources
Inteum Company News
Inteum Library
Subscribe
Search Results - oncology
72
Results
Sort By:
Published Date
Updated Date
Title
ID
Descending
Ascending
Using Nanotechnology to Target Aggressive Cancers
A modified gold nanoparticle is used to target aggressive triple negative breast cancer and melanoma by inhibiting RAD6 which is overexpressed in aggressive and chemoresistant cancers. Technology Summary This technology utilizes gold nanoparticles (GNPs) conjugated with a small molecule inhibitor (SMI#9) designed to target RAD6, a protein overexpressed...
Published: 8/22/2025
|
Inventor(s):
Malathy Shekhar
,
Guangzhao Mao
,
Yanhua Zhang
Keywords(s):
Breast Cancer
,
Nanotechnology
Category(s):
Life Science
,
Oncology
,
Drug Delivery
,
Therapeutics
,
Cancer
,
Nanomaterials
Novel tasquinimod analogs having novel anticancer activity
Project ID: TECH-2025-31 Background Disruption of microtubules has dramatic effects on cell division due to the essential role they play in conjunction with the mitotic spindles during this process. Molecules that disrupt microtubule function are currently in widespread clinical use in cancer treatment. Taxanes, vinca alkaloids, and epothilones are...
Published: 6/25/2025
|
Inventor(s):
Ghassan Abushaikha
,
William Taylor
Keywords(s):
Category(s):
Oncology
PTH1R PROTAC
Project ID: TECH-2025-20 Background Every 16 mins a man will die of Prostate cancer. Bone metastasis is the predominant cause of morbidity and mortality in prostate cancer, with > 80 % of lethal cases exhibiting skeletal involvement. Parathyroid hormone-related protein (PTHrP), secreted by tumor cells, binds and activates PTH1R on osteoblasts and...
Published: 6/25/2025
|
Inventor(s):
Xiaohong Li
,
Shang Su
,
Tim (Qingbin) Cui
,
Jian-Ting Zhang
Keywords(s):
Category(s):
Oncology
Confederated C Prime Agents vs Cancers (PDAC) & Metabolic Disorders
Project ID: D2020-28 Background Based upon the success of a mixture of simvastatin (SIM) + metformin (Met) + digoxin (Dig), dubbed “C3”, for treating pancreatic ductal adenocarcinoma (PDAC) via a pleiotropic mechanism where attenuation of the BIRC5 pathway is a major component, we have pursued novel, single-molecular constructs that combine...
Published: 6/4/2025
|
Inventor(s):
Paul Erhardt
,
Shi-He Liu
,
F. Charles Brunicardi
,
Divya Andy
Keywords(s):
Category(s):
Oncology
Analogs of peroxisome proliferator activiated receptor (PPAR) agonists, and methods of using the same
Novel PPARδ Agonists for Bone Growth Background Osteoporosis is a silent disease of bones that affects tens of millions of people over the age of 50 with direct medical costs of over $31 billion yearly due to injuries from falls. With the aging population of the US there is a serious need for effective treatments to combat bone...
Published: 3/27/2025
|
Inventor(s):
Bruce Heck
,
Paul Erhardt
,
Brian Kress
,
DongHyun Kim
Keywords(s):
Category(s):
Long Bone/Joint Repair
,
Oncology
A novel approach to the treatment of EGFR mutant non-small cell lung cancer (NSCLC)
Background Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for ~85% of all lung cancer cases. NSCLC is slow growing and often diagnosed at later stages when it has already spread, making treatment difficult. Resistance to therapy is a major challenge in effectively treating patients with NSCLC. 10-30% of...
Published: 8/14/2025
|
Inventor(s):
Jack Elias
,
Suchitra Kamle
,
Chun Geun Lee
,
Bing Ma
Keywords(s):
Category(s):
Oncology
Advancement in Platinum Based Cancer Therapeutics
Project ID: D2013-02 Novelty: Small drug like molecules that inhibits DNA repair factors for cisplatin (and other platinum based drugs) resistance towards solid tumors, thereby increasing cisplatin cytotoxicity and efficacy. Value proposition: One of the limitations of chemotherapy in ovarian cancer is the innate/acquired drug resistance in cancer...
Published: 1/2/2025
|
Inventor(s):
Stephan Patrick
,
Paul Erhardt
Keywords(s):
Cisplatin
,
Clinical Trials
,
DNA Repair
,
Ovarian Cancer
,
Platinum
Category(s):
Oncology
S100A4 Monoclonal Antibody for Therapeutic and Diagnostic Use
Cancer metastasis are responsible for ~90% of cancer associated deaths. Recent studies suggest that immune cells play critical roles in promoting metastasis, especially myeloid cells from the bone marrow. UTHealth researchers, with researchers from Houston Methodist Hospital, observed a highly conserved expression of S100A4 in immune suppressive myeloid...
Published: 5/9/2025
|
Inventor(s):
Zhiqiang An
,
Ningyan Zhang
Keywords(s):
Category(s):
Neurology/Neurosurgery
,
Oncology
,
Therapeutics
Survivin Inhibitors for Targeted Cancer Treatment
Project ID: TECH-2024-07 Background Prostate cancer is one of the most common cancers and the second-most lethal cancer among men in the United States. While the response to standard androgen deprivation therapy (ADT) is often dramatic, most prostate cancer patients develop resistance to ADT, leading to castration-resistant prostate cancer (CRPC)....
Published: 2/13/2025
|
Inventor(s):
Jian-Ting Zhang
,
Jasmine (JingYuan) Liu
,
Tim (Qingbin) Cui
Keywords(s):
Category(s):
Oncology
Monoclonal Antibodies Against PCDH7 for Therapeutic and Diagnostic Use
Non-small cell lung cancer (NSCLC) is the leading cause of cancer-associated deaths worldwide. UTHealth researchers discovered that the cell surface protein Protocadherin 7 (PCDH7) is highly expressed in NSCLC and promotes lung cancer development. Inventors at UTH in collaboration with Dr. O’Donnell’s group at UTSW have discovered a panel...
Published: 3/24/2025
|
Inventor(s):
Zhiqiang An
,
Ningyan Zhang
,
Kathryn O'Donnell
Keywords(s):
Category(s):
Diagnostics
,
Oncology
,
Therapeutics
,
Biologics
1
2
3
4
5
6
7
8